lovastatin
Selected indexed studies
- Lovastatin alleviates DSS-induced colitis by modulating macrophage polarization via the PPARγ-NF-κB pathway. (Int Immunopharmacol, 2025) [PMID:40505233]
- Lovastatin for hypercholesterolemia. (Drug Intell Clin Pharm, 1988) [PMID:3046888]
- Lovastatin: a new cholesterol-lowering agent. (Pharmacotherapy, 1987) [PMID:3328165]
_Worker-drafted node — pending editorial review._
Connections
lovastatin is a side effect of
Sources
- Lovastatin alleviates DSS-induced colitis by modulating macrophage polarization via the PPARγ-NF-κB pathway. (2025) pubmed
- Lovastatin for hypercholesterolemia. (1988) pubmed
- Lovastatin: a new cholesterol-lowering agent. (1987) pubmed
- Lovastatin production: From molecular basis to industrial process optimization. (2015) pubmed
- Lovastatin extended release: a review of its use in the management of hypercholesterolaemia. (2003) pubmed
- An overview on the biosynthesis and metabolic regulation of monacolin K/lovastatin. (2020) pubmed
- Production of lovastatin and itaconic acid by Aspergillus terreus: a comparative perspective. (2017) pubmed
- An overview on the biological activity and anti-cancer mechanism of lovastatin. (2021) pubmed
- Shape-dependent bioavailability of lovastatin nanocrystals. (2019) pubmed
- Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade. (2020) pubmed